BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cree IA, Charlton P. Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer. 2017;17:10. [PMID: 28056859 DOI: 10.1186/s12885-016-2999-1] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 21.6] [Reference Citation Analysis]
Number Citing Articles
1 Ghosh S, Lalani R, Patel V, Bardoliwala D, Maiti K, Banerjee S, Bhowmick S, Misra A. Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies. Journal of Controlled Release 2019;296:114-39. [DOI: 10.1016/j.jconrel.2019.01.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
2 Aniogo EC, Plackal Adimuriyil George B, Abrahamse H. The role of photodynamic therapy on multidrug resistant breast cancer. Cancer Cell Int 2019;19:91. [PMID: 31007609 DOI: 10.1186/s12935-019-0815-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
3 Pienta KJ, Hammarlund EU, Axelrod R, Amend SR, Brown JS. Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer. Mol Cancer Res 2020;18:801-10. [PMID: 32234827 DOI: 10.1158/1541-7786.MCR-19-1158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
4 Meng QB, Peng JJ, Qu ZW, Zhu XM, Wen Z, Kang WM. Eukaryotic initiation factor 5A2 and human digestive system neoplasms. World J Gastrointest Oncol 2019; 11(6): 449-458 [PMID: 31236196 DOI: 10.4251/wjgo.v11.i6.449] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Shahar N, Larisch S. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resistance Updates 2020;52:100712. [DOI: 10.1016/j.drup.2020.100712] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
6 Manley PW, Caravatti G, Furet P, Roesel J, Tran P, Wagner T, Wartmann M. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy. Biochemistry 2018;57:5576-90. [PMID: 30148617 DOI: 10.1021/acs.biochem.8b00727] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
7 Nanayakkara AK, Vogel PD, Wise JG. Prolonged inhibition of P-glycoprotein after exposure to chemotherapeutics increases cell mortality in multidrug resistant cultured cancer cells. PLoS One 2019;14:e0217940. [PMID: 31173617 DOI: 10.1371/journal.pone.0217940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 Zhang C, Hao Y, Sun Y, Liu P. Quercetin suppresses the tumorigenesis of oral squamous cell carcinoma by regulating microRNA-22/WNT1/β-catenin axis. Journal of Pharmacological Sciences 2019;140:128-36. [DOI: 10.1016/j.jphs.2019.03.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
9 Kovachka S, Malloci G, Simsir M, Ruggerone P, Azoulay S, Mus-veteau I. Inhibition of the drug efflux activity of Ptch1 as a promising strategy to overcome chemotherapy resistance in cancer cells. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114306] [Reference Citation Analysis]
10 Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, Milardi D, Lacal PM, Marini S, Purrello R, Graziani G, Coletta M. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther 2020;213:107579. [PMID: 32442437 DOI: 10.1016/j.pharmthera.2020.107579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
11 Prajapati J, Goswami D, Rawal RM. Endophytic fungi: A treasure trove of novel anticancer compounds. Curr Res Pharmacol Drug Discov 2021;2:100050. [PMID: 34909676 DOI: 10.1016/j.crphar.2021.100050] [Reference Citation Analysis]
12 Sheikine Y, Pavlick D, Klempner SJ, Trabucco SE, Chung JH, Rosenzweig M, Wang K, Velcheti V, Frampton GM, Peled N, Murray M, Chae YK, Albacker LA, Gay L, Husain H, Suh JH, Millis SZ, Reddy VP, Elvin JA, Hartmaier RJ, Dowlati A, Stephens P, Ross JS, Bivona TG, Miller VA, Ganesan S, Schrock AB, Ou SI, Ali SM. BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precis Oncol 2018;2:PO. [PMID: 32913992 DOI: 10.1200/PO.17.00172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kong X, Hu S, Yuan Y, Du Y, Zhu Z, Song Z, Lu S, Zhao C, Yan D. Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. J Cancer 2020;11:3357-68. [PMID: 32231742 DOI: 10.7150/jca.40729] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
14 Güçlü E, Eroğlu Güneş C, Kurar E, Vural H. Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy. Med Oncol 2021;38:113. [PMID: 34378101 DOI: 10.1007/s12032-021-01562-2] [Reference Citation Analysis]
15 Wang J, Hu Y, Escamilla-Rivera V, Gonzalez CL, Tang L, Wang B, El-Naggar AK, Myers JN, Caulin C. Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. Cancers (Basel) 2021;13:1471. [PMID: 33806894 DOI: 10.3390/cancers13061471] [Reference Citation Analysis]
16 Valletti A, Marzano F, Pesole G, Sbisà E, Tullo A. Targeting Chemoresistant Tumors: Could TRIM Proteins-p53 Axis Be a Possible Answer? Int J Mol Sci 2019;20:E1776. [PMID: 30974870 DOI: 10.3390/ijms20071776] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
17 Wang S, Zou Z, Luo X, Mi Y, Chang H, Xing D. LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer. Oncogene 2018;37:3243-59. [DOI: 10.1038/s41388-018-0193-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
18 Jauset T, Beaulieu ME. Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead. Curr Opin Pharmacol 2019;47:133-40. [PMID: 31048179 DOI: 10.1016/j.coph.2019.03.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
19 Muñoz-Pérez MJ, Casco S, Garza-González MDC, Soto-Vega E. P-glycoprotein Activity Correlates With Treatment Response in 2 Leukemia Child Patients. J Pediatr Hematol Oncol 2018;40:e490-4. [PMID: 30124547 DOI: 10.1097/MPH.0000000000001278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Pienta KJ, Hammarlund EU, Axelrod R, Brown JS, Amend SR. Poly-aneuploid cancer cells promote evolvability, generating lethal cancer. Evol Appl 2020;13:1626-34. [PMID: 32952609 DOI: 10.1111/eva.12929] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
21 de Oliveira Júnior RG, Christiane Adrielly AF, da Silva Almeida JRG, Grougnet R, Thiéry V, Picot L. Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms. Fitoterapia 2018;129:383-400. [DOI: 10.1016/j.fitote.2018.02.025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
22 Liu K, Luo J, Shao C, Ren Z, Sun S, Zhu Y, Zhou H, Jiang Z, Li X, Gu W, Xu Y, Qiang Y, Ren B, Xu L, Wu H, Shen Y. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Med Sci Monit 2020;26:e920351. [PMID: 32108133 DOI: 10.12659/MSM.920351] [Reference Citation Analysis]
23 Feliz Morel ÁJ, Hasanovic A, Morin A, Prunier C, Magnone V, Lebrigand K, Aouad A, Cogoluegnes S, Favier J, Pasquier C, Mus-veteau I. Persistent Properties of a Subpopulation of Cancer Cells Overexpressing the Hedgehog Receptor Patched. Pharmaceutics 2022;14:988. [DOI: 10.3390/pharmaceutics14050988] [Reference Citation Analysis]
24 Romano D. Relevance of neuroendocrine tumours models assessed by kinomic profiling. Ann Endocrinol (Paris) 2019;80:144-8. [PMID: 31054767 DOI: 10.1016/j.ando.2019.04.008] [Reference Citation Analysis]
25 Gomes BC, Honrado M, Armada A, Viveiros M, Rueff J, Rodrigues AS. ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance. Int J Mol Sci 2020;21:E2985. [PMID: 32340269 DOI: 10.3390/ijms21082985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Dawood M, Hamdoun S, Efferth T. Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology. Front Pharmacol 2018;9:143. [PMID: 29535630 DOI: 10.3389/fphar.2018.00143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
27 Wang W, Hao Y, Liu Y, Li R, Huang DB, Pan YY. Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1654. [PMID: 32700465 DOI: 10.1002/wnan.1654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Uddin N, Rashid F, Ali S, Tirmizi SA, Ahmad I, Zaib S, Zubair M, Diaconescu PL, Tahir MN, Iqbal J, Haider A. Synthesis, characterization, and anticancer activity of Schiff bases. J Biomol Struct Dyn 2020;38:3246-59. [PMID: 31411114 DOI: 10.1080/07391102.2019.1654924] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
29 Agnello L, Camorani S, Fedele M, Cerchia L. Aptamers and antibodies: rivals or allies in cancer targeted therapy? Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Cassinelli G, Dal Bo L, Favini E, Cominetti D, Pozzi S, Tortoreto M, De Cesare M, Lecis D, Scanziani E, Minoli L, Naggi A, Vlodavsky I, Zaffaroni N, Lanzi C. Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases. Cancer Lett 2018;415:187-97. [PMID: 29225052 DOI: 10.1016/j.canlet.2017.12.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
31 Singh A, Amiji M. The future of drug delivery in cancer treatment. Biomaterials for Cancer Therapeutics. Elsevier; 2020. pp. 569-97. [DOI: 10.1016/b978-0-08-102983-1.00021-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Morales-Cruz M, Delgado Y, Castillo B, Figueroa CM, Molina AM, Torres A, Milián M, Griebenow K. Smart Targeting To Improve Cancer Therapeutics. Drug Des Devel Ther 2019;13:3753-72. [PMID: 31802849 DOI: 10.2147/DDDT.S219489] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 9.3] [Reference Citation Analysis]
33 Wu N, Huang Y, Zou Z, Gimenez-Capitan A, Yu L, Hu W, Zhu L, Sun X, Sanchez JJ, Guan W, Liu B, Rosell R, Wei J. High BIM mRNA levels are associated with longer survival in advanced gastric cancer. Oncol Lett 2017;13:1826-34. [PMID: 28454330 DOI: 10.3892/ol.2017.5660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
34 Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: An update and perspective. Drug Resist Updat 2021;:100796. [PMID: 34953682 DOI: 10.1016/j.drup.2021.100796] [Reference Citation Analysis]
35 Lim JH, Choi KH, Kim SY, Park CS, Kim SM, Park KC. Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis. Int J Mol Sci 2020;21:E7469. [PMID: 33050525 DOI: 10.3390/ijms21207469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Langut Y, Edinger N, Flashner-Abramson E, Melamed-Book N, Lebendiker M, Levi-Kalisman Y, Klein S, Levitzki A. PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses. Oncotarget 2017;8:24046-62. [PMID: 28445962 DOI: 10.18632/oncotarget.15733] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Manda G, Hinescu ME, Neagoe IV, Ferreira LF, Boscencu R, Vasos P, Basaga SH, Cuadrado A. Emerging Therapeutic Targets in Oncologic Photodynamic Therapy. CPD 2019;24:5268-95. [DOI: 10.2174/1381612825666190122163832] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
38 Elton TS, Ozer HG, Yalowich JC. Effects of DNA topoisomerase IIα splice variants on acquired drug resistance. Cancer Drug Resist 2020;3:161-70. [PMID: 32566920 DOI: 10.20517/cdr.2019.117] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
39 Gallogly MM, Lazarus HM, Cooper BW. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Ther Adv Hematol 2017;8:245-61. [PMID: 29051803 DOI: 10.1177/2040620717721459] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
40 Alcon C, Gómez Tejeda Zañudo J, Albert R, Wagle N, Scaltriti M, Letai A, Samitier J, Montero J. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells 2021;10:1659. [PMID: 34359829 DOI: 10.3390/cells10071659] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Guo Q, Li X, Cui MN, Sun JL, Ji HY, Ni BB, Yan MX. CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy. Oncol Res 2020;28:533-40. [PMID: 32532363 DOI: 10.3727/096504020X15919605976853] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Han JH, Kim M, Kim HJ, Jang SB, Bae SJ, Lee IK, Ryu D, Ha KT. Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil. Int J Mol Sci 2021;22:5406. [PMID: 34065602 DOI: 10.3390/ijms22105406] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Gacche RN, Assaraf YG. Redundant angiogenic signaling and tumor drug resistance. Drug Resistance Updates 2018;36:47-76. [DOI: 10.1016/j.drup.2018.01.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
44 Huang S, Zhang QY, He AE, Li HB, Zhang ZX. Sex determining region Y-box 9 induced microtubule formation and epithelial⁃mesenchymal transition in human oral squamous cell carcinoma CAL27 cells. Hua Xi Kou Qiang Yi Xue Za Zhi 2021;39:74-80. [PMID: 33723940 DOI: 10.7518/hxkq.2021.01.011] [Reference Citation Analysis]
45 del Corte X, López-francés A, Villate-beitia I, Sainz-ramos M, Martínez de Marigorta E, Palacios F, Alonso C, de los Santos JM, Pedraz JL, Vicario J. Multicomponent Synthesis of Unsaturated γ-Lactam Derivatives. Applications as Antiproliferative Agents through the Bioisosterism Approach: Carbonyl vs. Phosphoryl Group. Pharmaceuticals 2022;15:511. [DOI: 10.3390/ph15050511] [Reference Citation Analysis]
46 Pienta KJ, Hammarlund EU, Austin RH, Axelrod R, Brown JS, Amend SR. Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy. Semin Cancer Biol 2020:S1044-579X(20)30254-6. [PMID: 33276091 DOI: 10.1016/j.semcancer.2020.11.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
47 Moeckel S, LaFrance K, Wetsch J, Seliger C, Riemenschneider MJ, Proescholdt M, Hau P, Vollmann-Zwerenz A. ATF4 contributes to autophagy and survival in sunitinib treated brain tumor initiating cells (BTICs). Oncotarget 2019;10:368-82. [PMID: 30719230 DOI: 10.18632/oncotarget.26569] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
48 Pérez-Velázquez J, Rejniak KA. Drug-Induced Resistance in Micrometastases: Analysis of Spatio-Temporal Cell Lineages. Front Physiol 2020;11:319. [PMID: 32362836 DOI: 10.3389/fphys.2020.00319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
49 Akbarzadeh M, Akbarzadeh S, Majidinia M. Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer. Pathol Res Pract 2020;216:153158. [PMID: 32829107 DOI: 10.1016/j.prp.2020.153158] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Bogusławska-Duch J, Ducher M, Małecki M. Resistance of melanoma cells to anticancer treatment: a role of vascular endothelial growth factor. Postepy Dermatol Alergol 2020;37:11-8. [PMID: 32467677 DOI: 10.5114/ada.2020.93378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Wani TH, Surendran S, Mishra VS, Chaturvedi J, Chowdhury G, Chakrabarty A. Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells. Oncotarget 2018;9:33589-600. [PMID: 30323901 DOI: 10.18632/oncotarget.26096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
52 Liu W, Sun Y, Ge W, Zhang F, Gan L, Zhu Y, Guo T, Liu K. DIA-based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia. Mol Cell Proteomics 2021;:100187. [PMID: 34922009 DOI: 10.1016/j.mcpro.2021.100187] [Reference Citation Analysis]
53 Battaglia AM, Sacco A, Perrotta ID, Faniello MC, Scalise M, Torella D, Levi S, Costanzo F, Biamonte F. Iron Administration Overcomes Resistance to Erastin-Mediated Ferroptosis in Ovarian Cancer Cells. Front Oncol 2022;12:868351. [DOI: 10.3389/fonc.2022.868351] [Reference Citation Analysis]
54 Whitaker RH, Placzek WJ. MCL1 binding to the reverse BH3 motif of P18INK4C couples cell survival to cell proliferation. Cell Death Dis 2020;11:156. [PMID: 32111816 DOI: 10.1038/s41419-020-2351-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Li L, Zhang C, Huang C, Tian X, Sun W, Jiang S, Heredia J. Research Advances in Antitumor Mechanism of Evodiamine. Journal of Chemistry 2022;2022:1-12. [DOI: 10.1155/2022/2784257] [Reference Citation Analysis]
56 Meng Q, Wang S, Zhou S, Liu H, Ma X, Zhou X, Liu H, Xu C, Jiang W. Dissecting the m6A methylation affection on afatinib resistance in non-small cell lung cancer. Pharmacogenomics J 2020;20:227-34. [DOI: 10.1038/s41397-019-0110-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
57 Zhou Y, Han Y, Li G, Yang S, Chu F. Lignin-Based Hollow Nanoparticles for Controlled Drug Delivery: Grafting Preparation Using β-Cyclodextrin/Enzymatic-Hydrolysis Lignin. Nanomaterials (Basel) 2019;9:E997. [PMID: 31373282 DOI: 10.3390/nano9070997] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
58 Gu L, Saha ST, Thomas J, Kaur M. Targeting cellular cholesterol for anticancer therapy. FEBS J 2019;286:4192-208. [DOI: 10.1111/febs.15018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
59 García-aranda M, Téllez T, Mckenna L, Redondo M. Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance. Cancers 2022;14:2255. [DOI: 10.3390/cancers14092255] [Reference Citation Analysis]
60 Qi FL, Wang MF, Li BZ, Lu ZF, Nie GJ, Li SP. Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells. Acta Pharmacol Sin 2020;41:895-901. [PMID: 32467568 DOI: 10.1038/s41401-020-0423-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Cortesi M, Liverani C, Mercatali L, Ibrahim T, Giordano E. Development and validation of an in-silico tool for the study of therapeutic agents in 3D cell cultures. Comput Biol Med 2021;130:104211. [PMID: 33476993 DOI: 10.1016/j.compbiomed.2021.104211] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Karthika C, Hari B, Rahman MH, Akter R, Najda A, Albadrani GM, Sayed AA, Akhtar MF, Abdel-Daim MM. Multiple strategies with the synergistic approach for addressing colorectal cancer. Biomed Pharmacother 2021;140:111704. [PMID: 34082400 DOI: 10.1016/j.biopha.2021.111704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Khan E, Hanif M, Akhtar MS. Schiff bases and their metal complexes with biologically compatible metal ions; biological importance, recent trends and future hopes. Reviews in Inorganic Chemistry 2021;0. [DOI: 10.1515/revic-2021-0034] [Reference Citation Analysis]
64 Liang YY, Bacanu S, Sreekumar L, Ramos AD, Dai L, Michaelis M, Cinatl J, Seki T, Cao Y, Coffill CR, Lane DP, Prabhu N, Nordlund P. CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity. Cell Chem Biol 2021:S2451-9456(21)00306-8. [PMID: 34265272 DOI: 10.1016/j.chembiol.2021.06.007] [Reference Citation Analysis]
65 Achar A, Myers R, Ghosh C. Drug Delivery Challenges in Brain Disorders across the Blood-Brain Barrier: Novel Methods and Future Considerations for Improved Therapy. Biomedicines 2021;9:1834. [PMID: 34944650 DOI: 10.3390/biomedicines9121834] [Reference Citation Analysis]
66 Singh A, Patel SK, Kumar P, Das KC, Verma D, Sharma R, Tripathi T, Giri R, Martins N, Garg N. Quercetin acts as a P-gp modulator via impeding signal transduction from nucleotide-binding domain to transmembrane domain. J Biomol Struct Dyn 2020;:1-9. [PMID: 33306006 DOI: 10.1080/07391102.2020.1858966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
67 Narayanan S, Cai C, Assaraf YG, Guo H, Cui Q, Wei L, Huang J, Ashby CR, Chen Z. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resistance Updates 2020;48:100663. [DOI: 10.1016/j.drup.2019.100663] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
68 Mashayekhi S, Yousefi B, Tohidi E, Darband SG, Mirza‐aghazadeh‐attari M, Sadighparvar S, Kaviani M, Shafiei‐irannejad V, Kafil HS, Karimian A, Jadidi‐niaragh F, Majidinia M. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin‐resistance leukemia cancer cells to treatment. J Cell Biochem 2019;120:15719-29. [DOI: 10.1002/jcb.28841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
69 Kawassaki RK, Romano M, Dietrich N, Araki K. Titanium and Iron Oxide Nanoparticles for Cancer Therapy: Surface Chemistry and Biological Implications. Front Nanotechnol 2021;3:735434. [DOI: 10.3389/fnano.2021.735434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Gómez Tejeda Zañudo J, Scaltriti M, Albert R. A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer. Cancer Converg 2017;1:5. [PMID: 29623959 DOI: 10.1186/s41236-017-0007-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
71 Bolandi SM, Pakjoo M, Beigi P, Kiani M, Allahgholipour A, Goudarzi N, Khorashad JS, Eiring AM. A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. Cells 2021;10:2833. [PMID: 34831055 DOI: 10.3390/cells10112833] [Reference Citation Analysis]
72 Alves C, Serrano E, Silva J, Rodrigues C, Pinteus S, Gaspar H, Botana LM, Alpoim MC, Pedrosa R. Sphaerococcus coronopifolius bromoterpenes as potential cancer stem cell-targeting agents. Biomed Pharmacother 2020;128:110275. [PMID: 32480221 DOI: 10.1016/j.biopha.2020.110275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Skowron MA, Petzsch P, Hardt K, Wagner N, Beier M, Stepanow S, Drechsler M, Rieder H, Köhrer K, Niegisch G, Hoffmann MJ, Schulz WA. Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines. Sci Rep 2019;9:14476. [PMID: 31597922 DOI: 10.1038/s41598-019-50891-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
74 Zhang Z, Ha SH, Moon YJ, Hussein UK, Song Y, Kim KM, Park SH, Park HS, Park BH, Ahn AR, Lee SA, Ahn SJ, Kim JR, Jang KY. Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma. J Exp Clin Cancer Res 2020;39:247. [PMID: 33198792 DOI: 10.1186/s13046-020-01759-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
75 Toupin NP, Steinke SJ, Herroon MK, Podgorski I, Turro C, Kodanko JJ. Unlocking the Potential of Ru(II) Dual-action Compounds with the Power of the Heavy-atom Effect. Photochem Photobiol 2021. [PMID: 34866185 DOI: 10.1111/php.13573] [Reference Citation Analysis]
76 Majera D, Mistrik M. Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells. Int J Mol Sci 2020;21:E9431. [PMID: 33322336 DOI: 10.3390/ijms21249431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Eguchi T, Taha EA, Calderwood SK, Ono K. A Novel Model of Cancer Drug Resistance: Oncosomal Release of Cytotoxic and Antibody-Based Drugs. Biology (Basel) 2020;9:E47. [PMID: 32150875 DOI: 10.3390/biology9030047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
78 Le HT, Nguyen HT, Min HY, Hyun SY, Kwon S, Lee Y, Le THV, Lee J, Park JH, Lee HY. Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells. Cancer Lett 2018;412:297-307. [PMID: 29061506 DOI: 10.1016/j.canlet.2017.10.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
79 Wong F, Coban O, Weitsman G, Ng T. Integrating imaging, exosome and protein network rewiring information to track early tumour evolution of resistance mechanisms. Converg Sci Phys Oncol 2017;3:013004. [DOI: 10.1088/2057-1739/aa5cbd] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
80 Kesharwani SS, Kaur S, Tummala H, Sangamwar AT. Overcoming multiple drug resistance in cancer using polymeric micelles. Expert Opinion on Drug Delivery 2018;15:1127-42. [DOI: 10.1080/17425247.2018.1537261] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
81 Pienta KJ, Hammarlund EU, Brown JS, Amend SR, Axelrod RM. Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells. Proc Natl Acad Sci U S A 2021;118:e2020838118. [PMID: 33504594 DOI: 10.1073/pnas.2020838118] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
82 Lal S, Snape TJ. A therapeutic update on PARP inhibitors: implications in the treatment of glioma. Drug Discov Today 2021;26:532-41. [PMID: 33157194 DOI: 10.1016/j.drudis.2020.10.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Ilan Y, Spigelman Z. Establishing patient-tailored variability-based paradigms for anti-cancer therapy: Using the inherent trajectories which underlie cancer for overcoming drug resistance. Cancer Treatment and Research Communications 2020;25:100240. [DOI: 10.1016/j.ctarc.2020.100240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
84 Quah SY, Wong CC, Wong HC, Ho KL, Abdul Manan N, Deb PK, Sagineedu SR, Stanslas J. Microarray-based identification of differentially expressed genes associated with andrographolide derivatives-induced resistance in colon and prostate cancer cell lines. Toxicol Appl Pharmacol 2021;425:115605. [PMID: 34087331 DOI: 10.1016/j.taap.2021.115605] [Reference Citation Analysis]
85 Toupin NP, Arora K, Shrestha P, Peterson JA, Fischer LJ, Rajagurubandara E, Podgorski I, Winter AH, Kodanko JJ. BODIPY-Caged Photoactivated Inhibitors of Cathepsin B Flip the Light Switch on Cancer Cell Apoptosis. ACS Chem Biol 2019;14:2833-40. [DOI: 10.1021/acschembio.9b00711] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
86 Catlow J, Bray B, Morris E, Rutter M. Power of big data to improve patient care in gastroenterology. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2019-101239] [Reference Citation Analysis]
87 Trembley JH, Kren BT, Abedin MJ, Vogel RI, Cannon CM, Unger GM, Ahmed K. CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer. Pharmaceuticals (Basel) 2017;10:E25. [PMID: 28230733 DOI: 10.3390/ph10010025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
88 Lai X, Hao W, Friedman A. TNF-α inhibitor reduces drug-resistance to anti-PD-1: A mathematical model. PLoS One 2020;15:e0231499. [PMID: 32310956 DOI: 10.1371/journal.pone.0231499] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Emrani S, Lamar M, Price CC, Baliga S, Wasserman V, Matusz E, Swenson R, Baliga G, Libon DJ. Assessing the capacity for mental manipulation in patients with statically-determined mild cognitive impairment using digital technology. Exploration of Medicine. [DOI: 10.37349/emed.2021.00034] [Reference Citation Analysis]
90 Sun Y, Wang C, Meng Q, Liu Z, Huo X, Sun P, Sun H, Ma X, Peng J, Liu K. Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca2+ -mediated apoptosis pathways in MCF-7/ADR and K562/ADR. J Cell Physiol 2018;233:3066-79. [PMID: 28681913 DOI: 10.1002/jcp.26087] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
91 Wang L, Zhao X, Fu J, Xu W, Yuan J. The Role of Tumour Metabolism in Cisplatin Resistance. Front Mol Biosci 2021;8:691795. [PMID: 34250022 DOI: 10.3389/fmolb.2021.691795] [Reference Citation Analysis]
92 Shamseddin M, Obacz J, Garnett MJ, Rintoul RC, Francies HE, Marciniak SJ. Use of preclinical models for malignant pleural mesothelioma. Thorax 2021:thoraxjnl-2020-216602. [PMID: 33692175 DOI: 10.1136/thoraxjnl-2020-216602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
93 Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov 2020;19:711-36. [PMID: 32884152 DOI: 10.1038/s41573-020-0076-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
94 Liu H, Wang S, Zhou S, Meng Q, Ma X, Song X, Wang L, Jiang W. Drug Resistance-Related Competing Interactions of lncRNA and mRNA across 19 Cancer Types. Mol Ther Nucleic Acids 2019;16:442-51. [PMID: 31048183 DOI: 10.1016/j.omtn.2019.03.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
95 Cornelison R, Llaneza DC, Landen CN. Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review. Int J Mol Sci 2017;18:E2171. [PMID: 29057791 DOI: 10.3390/ijms18102171] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
96 Yu T, Cheng H, Ding Z, Wang Z, Zhou L, Zhao P, Tan S, Xu X, Huang X, Liu M, Peng M, Qiu YA. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells. Mol Cell Endocrinol 2020;506:110762. [PMID: 32087276 DOI: 10.1016/j.mce.2020.110762] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
97 Kang H, Kim C, Ji E, Ahn S, Jung M, Hong Y, Kim W, Lee EK. The MicroRNA-551a/MEF2C Axis Regulates the Survival and Sphere Formation of Cancer Cells in Response to 5-Fluorouracil. Mol Cells 2019;42:175-82. [PMID: 30703870 DOI: 10.14348/molcells.2018.0288] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
98 Falone S, Santini S Jr, Cordone V, Di Emidio G, Tatone C, Cacchio M, Amicarelli F. Extremely Low-Frequency Magnetic Fields and Redox-Responsive Pathways Linked to Cancer Drug Resistance: Insights from Co-Exposure-Based In Vitro Studies. Front Public Health 2018;6:33. [PMID: 29527520 DOI: 10.3389/fpubh.2018.00033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
99 Dhiman N, Shagaghi N, Bhave M, Sumer H, Kingshott P, Rath SN. Selective Cytotoxicity of a Novel Trp-Rich Peptide against Lung Tumor Spheroids Encapsulated inside a 3D Microfluidic Device. Adv Biosyst 2020;4:e1900285. [PMID: 32293162 DOI: 10.1002/adbi.201900285] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
100 Quayle LA, Ottewell PD, Holen I. Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. Clin Exp Metastasis 2018;35:831-46. [PMID: 30377878 DOI: 10.1007/s10585-018-9946-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
101 Fernandes C, Suares D, Yergeri MC. Tumor Microenvironment Targeted Nanotherapy. Front Pharmacol 2018;9:1230. [PMID: 30429787 DOI: 10.3389/fphar.2018.01230] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
102 Costa B, Amorim I, Gärtner F, Vale N. Understanding Breast cancer: from conventional therapies to repurposed drugs. Eur J Pharm Sci 2020;151:105401. [PMID: 32504806 DOI: 10.1016/j.ejps.2020.105401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
103 Roncalli V, Lenz PH, Cieslak MC, Hartline DK. Complementary mechanisms for neurotoxin resistance in a copepod. Sci Rep 2017;7:14201. [PMID: 29079725 DOI: 10.1038/s41598-017-14545-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
104 Lu N, Yin Y, Yao Y, Zhang P. SNHG3/miR-2682-5p/HOXB8 promotes cell proliferation and migration in oral squamous cell carcinoma. Oral Dis 2021;27:1161-70. [PMID: 32989886 DOI: 10.1111/odi.13656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
105 Quarti J, Torres DNM, Ferreira E, Vidal RS, Casanova F, Chiarini LB, Fialho E, Rumjanek VM. Selective Cytotoxicity of Piperine Over Multidrug Resistance Leukemic Cells. Molecules 2021;26:934. [PMID: 33578817 DOI: 10.3390/molecules26040934] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Dhiman N, Kingshott P, Sumer H, Sharma CS, Rath SN. On-chip anticancer drug screening - Recent progress in microfluidic platforms to address challenges in chemotherapy. Biosens Bioelectron 2019;137:236-54. [PMID: 31121461 DOI: 10.1016/j.bios.2019.02.070] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
107 Kania EE, Carvajal-Moreno J, Hernandez VA, English A, Papa JL, Shkolnikov N, Ozer HG, Yilmaz AS, Yalowich JC, Elton TS. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase IIα in Human Leukemia K562 Cells with Acquired Resistance to Etoposide. Mol Pharmacol 2020;97:159-70. [PMID: 31836624 DOI: 10.1124/mol.119.118315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
108 Khatoon E, Banik K, Harsha C, Sailo BL, Thakur KK, Khwairakpam AD, Vikkurthi R, Devi TB, Gupta SC, Kunnumakkara AB. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Seminars in Cancer Biology 2020. [DOI: 10.1016/j.semcancer.2020.06.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
109 Szumilak M, Wiktorowska-Owczarek A, Stanczak A. Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance? Molecules 2021;26:2601. [PMID: 33946916 DOI: 10.3390/molecules26092601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Xu W, Zhou B, Zhao X, Zhu L, Xu J, Jiang Z, Chen D, Wei Q, Han M, Feng L, Wang S, Wang X, Zhou J, Jin H. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance. Int J Biol Sci 2018;14:1122-32. [PMID: 29989047 DOI: 10.7150/ijbs.25881] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
111 Tundo GR, Sbardella D, Oddone F, Grasso G, Marini S, Atzori MG, Santoro AM, Milardi D, Bellia F, Macari G, Graziani G, Polticelli F, Cascio P, Parravano M, Coletta M. Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug. Biomolecules 2022;12:315. [DOI: 10.3390/biom12020315] [Reference Citation Analysis]
112 Malik JA, Ahmed S, Jan B, Bender O, Al Hagbani T, Alqarni A, Anwar S. Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges. Biomed Pharmacother 2022;145:112375. [PMID: 34863612 DOI: 10.1016/j.biopha.2021.112375] [Reference Citation Analysis]
113 Gabra MM, Salmena L. microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview. Front Oncol 2017;7:255. [PMID: 29164055 DOI: 10.3389/fonc.2017.00255] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
114 Chen M, Yin X, Lu C, Chen X, Ba H, Cai J, Sun J. Mahanine induces apoptosis, cell cycle arrest, inhibition of cell migration, invasion and PI3K/AKT/mTOR signalling pathway in glioma cells and inhibits tumor growth in vivo. Chem Biol Interact 2019;299:1-7. [PMID: 30468732 DOI: 10.1016/j.cbi.2018.11.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
115 El-benhawy SA, El-sheredy HG, Ghanem HB, Abo El-soud AA. Berberine can amplify cytotoxic effect of radiotherapy by targeting cancer stem cells. Breast Cancer Management 2020;9:BMT41. [DOI: 10.2217/bmt-2020-0007] [Reference Citation Analysis]
116 Madden EC, Gorman AM, Logue SE, Samali A. Tumour Cell Secretome in Chemoresistance and Tumour Recurrence. Trends Cancer 2020;6:489-505. [PMID: 32460003 DOI: 10.1016/j.trecan.2020.02.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
117 Elmore LW, Greer SF, Daniels EC, Saxe CC, Melner MH, Krawiec GM, Cance WG, Phelps WC. Blueprint for cancer research: Critical gaps and opportunities. CA Cancer J Clin 2021;71:107-39. [PMID: 33326126 DOI: 10.3322/caac.21652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
118 Ono K, Murakami M, Tsubokura M. Was there an improvement in the years of life lost (YLLs) for non-communicable diseases in the Soma and Minamisoma cities of Fukushima after the 2011 disaster? A longitudinal study. BMJ Open 2022;12:e054716. [PMID: 35383063 DOI: 10.1136/bmjopen-2021-054716] [Reference Citation Analysis]